Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Microbot Medical Inc. - Common Stock (NQ:MBOT)

2.100 +0.260 (+14.13%)
Streaming Delayed Price Updated: 11:45 AM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Microbot Medical Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Announces Late-Breaking Abstract Acceptance at the Society of Interventional Radiology Annual Meeting
Acceptance reflects the high interest of the SIR scientific committee on the emerging role of endovascular robotics 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Strengthens Its Management Team in Support of the Anticipated Commercial Launch of LIBERTY®
Operations Leader to Enhance Operational Efficiencies by Managing Production Scale-up and Cost Reduction Activities to Support Commercialization 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors
Mr. Wilson has a Track Record of Leading Product Launches and Achieving Revenue Growth in the Endovascular Devices Market 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Closes $8.6 Million Registered Direct Offering
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Raises a Total of Approximately $11.8 Million in Gross Proceeds from Registered Direct Offering and Previously Announced ATM Facility
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Announces $7 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY®
Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Announces FDA Submission for the Commercialization of the LIBERTY® Endovascular Robotic System
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Global Medical Service Robotics Market Project to Exceed $20 Billion in 2024 with Additional Growth Expected
EQNX::TICKER_START (NASDAQ:JFBR),(NASDAQ:SERV),(NASDAQ:SYM),(NASDAQ:MBOT),(NYSE:MDT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Global Medical Service Robotics Market Project to Exceed $20 Billion in 2024 with Additional Growth Expected
From FN Media Group LLC
Via GlobeNewswire
News headline image
Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System
Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization
The ISO 13485 certification is a validation of the Company’s robust quality system 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System
The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center
As the third and final clinical site, Memorial Sloan Kettering Cancer Center joins Brigham Women’s Hospital and Baptist Hospital of Miami as sites for the pivotal human clinical trial 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Partners with Baptist Hospital of Miami to Participate in its Pivotal Human Clinical Trial
Following the Company’s recent FDA approval to commence its pivotal human clinical trial, Baptist Hospital of Miami is the second clinical site to enroll in the trial 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Announces Brigham and Women's Hospital as a Site for its Pivotal Human Clinical Trial
The Site Initiation Visit for the BWH clinical staff is complete and a shipment of LIBERTY investigational units was delivered 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial
The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular Robotic Surgical System, which together are expected to support a future 510(k)... 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™
The next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities for remote endovascular procedures 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Shares Status Following Recent Geopolitical Events
From Microbot Medical Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.